The GNRC unites three groups studying the neurobiology and pathophysiology of schizophrenia with a core of scientists in the Columbia Genome Center (CGC) working on """"""""genomic"""""""" strategies to identify schizophrenia-related genes. These GNRC has two major objectives. The first goal is to elucidate the neurobiological underpinnings of schizophrenia, including neurochemical abnormalities (in synaptic proteins and MAP2), and neuroimmunological abnormalities (relating to the immunogenicity of an abnormal chaperonin, hsp60). The key genes, proteins, protein-protein interactions, and regulatory mechanisms generated by these and other studies then provide the template for the first of two computational genomic """"""""search engines"""""""". The first engine is designed to elaborate biochemical and regulatory pathways by predicting novel protein-protein interactions based upon systematic phylogenetic homology searchers. By matching human genes and proteins with their orthologues in lower, well-characterized organisms, new patterns of interaction can be predicted. These new """"""""protein networks"""""""" thereby form a database of likely target genes for schizophrenia-related DNA alterations. The second goal of the GNRC is to combine molecular and computational strategies to systematically identify and characterize all genes in a given large schizophrenia-linked chromosomal region. A second """"""""search engine"""""""" will collect all genes and predicted genes from such regions and characterize their phylogenetic homology relationships. Simultaneously, we will use established high throughout technologies to sequence large segments of the linked regions and analyze for predicted protein coding regions. Together, these strategies will yield a new set of gene and protein sequences that form a positional candidate gene database. Next, the protein-interaction and positional candidate search engines will cross- analyze to predict high priority candidate genes. In the final phase of the proposal we will develop a strategy to DNA sequence multiple candidate genes in a collection of patient and control DNA samples. In this way we will generate a public database of schizophrenia-related DNA alterations that will lay the foundation for a DNA microchip assay for large samples. A significant feature of this """"""""genomic"""""""" search strategy is that it bypasses the necessity of detecting shared chromosomal segments, the basis of all current genetic search strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH059342-02
Application #
6336705
Study Section
Clinical Centers and Special Projects Review Committee (CCSP)
Project Start
2000-09-01
Project End
2001-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2000
Total Cost
$143,425
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Goetz, Raymond R; Corcoran, Cheryl; Yale, Scott et al. (2007) Validity of a 'proxy'for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). Schizophr Res 93:169-77
Kimhy, David; Yale, Scott; Goetz, Raymond R et al. (2006) The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull 32:274-8
Kayser, Jurgen; Tenke, Craig E (2006) Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: I. Evaluation with auditory oddball tasks. Clin Neurophysiol 117:348-68
Kayser, Jurgen; Tenke, Craig E (2006) Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: II. Adequacy of low-density estimates. Clin Neurophysiol 117:369-80
van Berckel, Bart N M; Kegeles, Lawrence S; Waterhouse, Rikki et al. (2006) Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 31:967-77
Slifstein, Mark; Narendran, Raj; Hwang, Dah-Ren et al. (2004) Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse 54:46-63
Slifstein, Mark; Hwang, Dah-Ren; Huang, Yiyun et al. (2004) In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 175:274-86
Waterhouse, Rikki N; Slifstein, Mark; Dumont, Filip et al. (2004) In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxy-phenyl)-N'-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor. Nucl Med Biol 31:939-48
Huang, Yiyun; Hwang, Dah-Ren; Bae, Sung-A et al. (2004) A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). Nucl Med Biol 31:543-56
Harkavy-Friedman, Jill M; Nelson, Elizabeth A; Venarde, David F et al. (2004) Suicidal behavior in schizophrenia and schizoaffective disorder: examining the role of depression. Suicide Life Threat Behav 34:66-76

Showing the most recent 10 out of 30 publications